Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

104.08 -1.88 (-1.77%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
54 55 Next >
Oil Declines Amid Prospects Of An Agreement Between Israel And Hamas. Powell Will Address The Us Congress Today
On Monday, the Dow Jones (US30) decreased by 0.08%, while the S&P 500 (US500) added 0.10%. The NASDAQ Technology Index (US100) closed positive 0.28%. 
Via Talk Markets
Topics Stocks
Exposures US Equities
7 Cheap Biotech Stocks With Major Upside Potential
While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks. 
Via InvestorPlace
Healthcare Stocks Continue To Lag The Market-Can Anything Help ?
Healthcare stocks continue to lag the market up about 6% YTD, helped by Large Cap Biopharma but hurt by United Health. 
Via Talk Markets
This Domino's Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
Amgen, Inc. Dividend Stock Analysis
Amgen Inc. is one of the world's leading biotech companies with major treatments for anemia, neutropenia, rheumatoid and psoriatic arthritis, psoriasis, cancer and osteoporosis. 
Via Talk Markets
Key Takeaways From Gilead Sciences Analyst Ratings
Via Benzinga
Gilead Sciences's Options Frenzy: What You Need to Know
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today
Via Benzinga
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals. 
Via InvestorPlace
Exposures Product Safety
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
These three undervalued biotech stocks have begun garnering investor attention as their treatments show promise. 
Via InvestorPlace
3 Magnificent Stocks Retirees Can Buy and Hold Forever
These stocks could be ideal for investors in their golden years. 
Via The Motley Fool
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
7 Dividend Stocks to Buy Now: June 2024
These dividend stocks to buy now will reward investors with income now and growth as the market breadth expands. 
Via InvestorPlace
DraftKings And Dell Were Among The 10 Biggest Large Cap Stock Gainers Last Week (June 16-June 22): Are These In Your Portfolio?
Top performers last week were SRPT (+29.50%), SIRI (+16.73%), TOST (+15.57%), GILD (+12.62%), CHWY (+10.59%), ACN (+9.80%), DKNG (+9.69%), DELL (+8.19%), ADSK (+7.99%), and GFI (+7.15%). 
Via Benzinga
MarketBeat Week in Review – 6/17 - 6/21
Markets were calmer this week, with the Dow index posting the biggest gains, but it's too early to tell if this is the start of a broader market rally 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
Top Analyst Reports For Abbott, BP & Gilead
Today's Research Daily features new research reports on 16 major stocks, including Abbott Laboratories, BP p.l.c.and Gilead Sciences, Inc., as well as two micro-cap stocks Smith-Midland Corp. and... 
Via Talk Markets
Nvidia Snaps 8-Week Winning Run, S&P 500 Marks Longest Streak Without A 2% Drop Since Great Recession, Oil Prices Stage Comeback: This Week In The Market
Stock market rally continues with new highs in S&P 500 and Nasdaq 100, driven by tech and semiconductor sectors, but concerns arise over lack of broad participation and high concentration in mega-cap... 
Via Benzinga
Topics Economy Stocks
Exposures Economy US Equities
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments. 
Via Benzinga
Why Gilead Sciences Stock Is Trading Higher Friday
On Thursday before the market opened, Gilead announced efficacy data for its possible HIV prevention drug, Lenacapavir. 
Via Benzinga
Pre-Market Movers - June 21, 2024
Sarepta jumps after announcing expanded approval of DMD drug and more news on today's top movers. 
Via Talk Markets
Gilead Sciences Stock Surges on HIV Treatment Trial Success
Gilead Sciences (NASDAQ: GILD) saw its stock jump nearly 10% yesterday after announcing groundbreaking results from its HIV treatment trial. 
Via MarketBeat
Exposures Product Safety
Defying the Norms: 3 High P/E Stocks With Room to Run
Gilead Sciences, Crowdstrike and DataDog might be the best high P/E stocks to buy, offering substantial growth despite elevated valuations. 
Via InvestorPlace
S&P 500, Nasdaq 100 Dip From Record Highs As Investors Take Chipmaker Profits; Energy Sector Rebounds, Yields Rise: What's Driving Markets Thursday?
After the Juneteenth holiday break, Wall Street reopened with a cautious tone, as the S&P 500 and Nasdaq 100 indices declined after hitting all-time highs around midday trading in New York. This... 
Via Benzinga
Topics Stocks
Exposures US Equities
Gilead Flashes A Bullish Sign After HIV Drug Proves 100% Effective
The company tested its HIV prevention drug in cisgender women in Uganda and South Africa. 
Via Investor's Business Daily
Why Is Gilead Sciences Stock Trading Higher On Thursday?
Gilead Sciences announced its Phase 3 PURPOSE 1 trial results showing 100% efficacy of twice-yearly injectable lenacapavir in preventing HIV-1 in cisgender women. The trial met key efficacy endpoints,... 
Via Benzinga
KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END 
Via FinancialNewsMedia
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
From FN Media Group LLC
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
54 55 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.